Clinical Trials Directory

Phase II Trial of CC-5013 (Lenalidomide, RevlimidŽ) in Patients With Cutaneous T-Cell Lymphoma

RATIONALE: Lenalidomide may stop the growth of mycosis fungoides/Sezary syndrome by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with relapsed mycosis fungoides/Sezary syndrome.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : lenalidomide

Phase: Phase 2


Ages Eligible For Study:

18 Years - N/A

External Links

Explore related trials

Contact information

Primary Contact:

Natalie Viakhireva 6507238949

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: